comparemela.com

Latest Breaking News On - European society for blood - Page 8 : comparemela.com

Nexcella, an Immix Biopharma subsidiary, Announces Positive 58-Patient NXC-201 Clinical Data: 100% Overall Response Rate in Light Chain (AL) Amyloidosis; 92% Overall Response Rate in Multiple Myeloma at the EBMT 49th Annual Meeting in Paris

Multiple Myeloma 92% was the overall response rate produced by NXC-201 in relapsed/refractory multiple myeloma patients treated at the therapeutic dose of 800 million CAR+T cells in its. | April 26, 2023

United statesFrance generalIlya rachmanSuzanne messerePolina stepenskyGabriel morrisBeigene novartiView researchNexcella incImmix biopharma incInternational myeloma working groupEuropean society for bloodExchange commissionClinical cancer researchHadassah medical centerMultiple myeloma

Nexcella Announces Positive 58-Patient NXC- 201 Clinical Data: 100% Overall Response Rate in

Multiple Myeloma

France generalUnited statesIlya rachmanLos angelesPolina stepenskySuzanne messereGabriel morrisCompany contactEuropean society for bloodInternational myeloma working groupView researchNexcella incExchange commissionHadassah medical centerClinical cancer researchImmix biopharma inc

Medigene AG presents final Phase I data of TCR-T cell therapy MDG1011 in patients with high-risk blood cancers

MDG1011 was generally well tolerated in nine heavily pre-treated patients across three ascending dose levelsNo neurotoxicity or dose-limiting toxicities observedTwo out of nine patients showed early. | June 18, 2023

France generalPamela keckDolores schendelEuropean society for bloodHongsheng sciencesPrime standardEuropean societyMarrow transplantationFirst in human studyHigh risk myeloidLymphoid neoplasmsChief scientific officerPrecision pairing

Medigene reveals pivotal blood cancer therapy data

MDG1011 is a therapy which aims to improve outcomes for in patients with high-risk blood cancers - News - PharmaTimes

Dolores schendelEuropean society for bloodEuropean societyMarrow transplantation

Fresenius Kabi launches single-needle option for ECP system

Fresenius Kabi announced the availability of a single-needle venous access option for its Amicus extracorporeal photopheresis (ECP) system.

Fresenius kabiEuropean society for bloodEuropean societyMarrow transplantationAmicus blueAmicus separator

vimarsana © 2020. All Rights Reserved.